GlassScriptPhysician profile
Seema Sameer Verma
NPI 1609165661
$5,382.30
in general payments reported to CMS, 2019-2025
34 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $240 · 2021: $270 · 2022: $638 · 2023: $1,270 · 2024: $862 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $577.13 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $424.89 | 2019-2024 | Xarelto |
| Biosense Webster, INC. | $392.18 | 2023 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $368.31 | 2019-2025 | Farxiga |
| Medtronic, INC. | $361.89 | 2021-2025 | Micra |
| Merck Sharp & Dohme LLC | $320.83 | 2023-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.90 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $281.25 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $230.42 | 2019-2025 | Repatha, Repatha, Otezla |
| Boston Scientific Corporation | $225.27 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Exact Sciences Corporation | $214.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cvrx, INC. | $203.88 | 2023-2025 | Barostim Neo System |
| Abiomed | $201.24 | 2019-2023 | Impella |
| W. L. Gore & Associates, INC. | $186.34 | 2019 | |
| Stryker Corporation | $163.35 | 2025 | Blueprint Patient Specific Instrumentation, Limflow System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $112.18 | 2021-2024 | Aveir, Eterna |
| Heartflow, INC. | $107.95 | 2023 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.71 | 2021-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $82.79 | 2022 | |
| Pfizer INC. | $62.35 | 2019-2025 | |
| Philips North America LLC | $60.17 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.97 | 2024-2025 | |
| Medtronic Vascular, INC. | $42.59 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $41.43 | 2024 | Arcalyst |
| Lucid Diagnostics INC. | $38.08 | 2022-2023 | |
| Lilly USA, LLC | $33.88 | 2022-2025 | Zepbound, Mounjaro |
| Atricure, INC. | $27.94 | 2023 | |
| Edwards Lifesciences Corporation | $23.62 | 2023 | |
| Vital Connect, INC | $22.74 | 2025 | Vitalpatch Rtm |
| Novo Nordisk INC | $20.45 | 2023 | Ozempic |
| Inspire Medical Systems, INC. | $19.37 | 2024 | Inspire |
| Impulse Dynamics (USA) INC. | $18.43 | 2024 | Optimizer |
| Chiesi USA, INC. | $16.57 | 2019 | |
| Cardiovascular Systems INC. | $16.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.